AxeroVision is developing novel therapies for the treatment of ophthalmic inflammatory diseases, such as Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). AXR-159 is being developed for the treatment of chronic DED. AXR-270 is being developed for the short-term treatment of DED. Both assets have achieved clinical proof-of-concept.
View Top Employees from AxeroVision, Inc.Website | https://www.axerovision.com/ |
Employees | View employees |
Founded | 2016 |
Address | 5857 Owens Ave, Carlsbad, California 92008, US |
Industry | Biotechnology Research |
Looking for a particular AxeroVision, Inc. employee's phone or email?
AxeroVision, Inc. is based in Carlsbad, California.